AstraZeneca took the excuse of oversupply to remove COVID-19 vaccine globally and said that it had nothing to do with possible side effects
ehmhb25
发表于 2024-5-8 19:11:21
1269
0
0
AstraZeneca, a British pharmaceutical company, said on May 7 that there has been a surplus of available vaccines since the outbreak of COVID-19, and the company has begun to remove NewCrown vaccines globally. The company said in a statement that its decision was based on commercial considerations. With the development of a variety of vaccines to respond to the variant COVID-19, there has been a surplus of available booster needles, which has led to a decline in the demand for the company's COVID-19 vaccine Vaxzevria. Therefore, AstraZeneca has begun to recycle vaccines globally and will also revoke the marketing authorization of vaccines in Europe. AstraZeneca admitted in a legal document submitted to the court earlier this year that its vaccine "can cause thrombosis and thrombocytopenia in rare cases, and its pathogenic mechanism is not yet clear." However, AstraZeneca stated that the decision to remove the vaccine this time is not related to court cases or the company's recognition that the vaccine may cause side effects in some recipients.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Merck: Plan to conduct clinical trials of a new multivalent HPV vaccine
- GLP-1, the "elixir of all gold", has been exposed to have the latest side effect: an increased risk of unintended pregnancy
- Jia Yueting's End of Car Making! Faraday will be delisted in the future
- Failure to submit financial reports in a timely manner, warning of withdrawal and delisting of Polar Star Motors
- Failure to submit annual report in a timely manner, warning of delisting from Polestar Storage Nasdaq! Previously, the CEO stated that they would strengthen their market layout in China
- Sanofi infant syncytial virus nasal spray vaccine approved for clinical use in China
- Sanofi infant syncytial virus nasal spray vaccine approved for clinical use in China
- Moderna's second mRNA vaccine has been approved for market launch. Aimei is launching a challenge with two heavyweight mRNA vaccine products
- NASDAQ plans to tighten the "1-yuan delisting" rule, and the US stock market will increase delisting efforts
- Vaccine giant responds: nationwide suspension
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏